These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 8463726)
1. Fluoroquinolones and their adverse effects. Girdhar BK Indian J Lepr; 1993; 65(1):69-79. PubMed ID: 8463726 [No Abstract] [Full Text] [Related]
2. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Alangaden GJ; Lerner SA Clin Infect Dis; 1997 Nov; 25(5):1213-21. PubMed ID: 9402384 [TBL] [Abstract][Full Text] [Related]
3. Regarding Brasil, et al.'s adverse effects in leprosy's WHO/MDT and paramedic's role in leprosy control program. Cunha Mda G; Schettini AP; Pereira ES; Pedrosa VL; Cruz RC; Sadahiro M Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):257-9. PubMed ID: 9251600 [No Abstract] [Full Text] [Related]
4. [The role of the new quinolones in the treatment and prevention of tuberculosis and other infections caused by mycobacterium]. Ciruelos E; Zalazaín R; Sobradillo V Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():34-8. PubMed ID: 10563109 [No Abstract] [Full Text] [Related]
5. [Therapeutic use of fluoroquinolones]. Lumio J Duodecim; 1999; 115(3):304-15. PubMed ID: 11830877 [No Abstract] [Full Text] [Related]
6. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Talan DA Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831 [TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin: new preparation. A me-too with more cardiac risks. Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694 [TBL] [Abstract][Full Text] [Related]
8. An updated safety profile of moxifloxacin. Iannini PB; Mandell LA J Chemother; 2002 Feb; 14 Suppl 2():29-34. PubMed ID: 12003138 [No Abstract] [Full Text] [Related]
9. [Fluoroquinolones--a current review]. Christ W; Kemmler H Med Monatsschr Pharm; 2001 Jul; 24(7):215-25. PubMed ID: 11486553 [No Abstract] [Full Text] [Related]
10. [Recent fluoroquinolones. Highly effective weapons for ambulatory therapy]. Stahlmann R; Lode H MMW Fortschr Med; 1999 Nov; 141(47):35-6. PubMed ID: 10912165 [No Abstract] [Full Text] [Related]
11. Choosing the ideal antibiotic therapy and the role of the newer fluoroquinolones in respiratory tract infections. Owens RC Am J Manag Care; 2000 May; 6(8 Suppl):S442-7. PubMed ID: 10977484 [No Abstract] [Full Text] [Related]
12. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648. Tomioka H Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623 [TBL] [Abstract][Full Text] [Related]
14. [Question marks about the use of enrofloxacin in sport horses]. Oostra F Tijdschr Diergeneeskd; 2003 Feb; 128(4):124. PubMed ID: 12625163 [No Abstract] [Full Text] [Related]
15. Use of fluoroquinolones: practical considerations. Ponte CD; Fisher MA Am Fam Physician; 1993 Apr; 47(5):1243-9. PubMed ID: 8465719 [TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones in children: poorly defined risk of joint damage. Prescrire Int; 2004 Oct; 13(73):184-6. PubMed ID: 15499700 [TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolones: a new treatment for tuberculosis? Gillespie SH; Kennedy N Int J Tuberc Lung Dis; 1998 Apr; 2(4):265-71. PubMed ID: 9559396 [TBL] [Abstract][Full Text] [Related]